• Stem Cells

    Be informed about arguments for storing and therapeutic possibilities

    More...
  • Collection

    What you need to know, what you have to do. Step by step about the collection process

    More...
  • Our Services

    Various packages to meet your different demands. Get to know our premium services!

    More...
  • Why KriOvum?

    All what makes you feel safe. Quality assurance, referencies, guaranties

    More...
  • FAQs

    Frequently Asked Questions. Do you need more information? Feel free to contact!

    More...

More about our premium service

Freezing and storage umbilical cord blood and cord tissue

for 20 years with the latest technology

In our premium service we isolate and identify the segment rich in mesenchymal stem cells using the special procedure developed by the Fami Cord Group. The process takes at least 5 weeks and 5 separate vials are used for the final storage.

  • Get to know more about the advantages of preserving umbilical cord!

What is Wharton’s jelly?

Wharton’s jelly is the tissue, or matrix, of the umbilical cord containing the blood vessels. These blood vessels can be used for collecting UCB-derived stem cells (see figure).

What is the difference between the mesenchymal stem cells collected from Wharton’s jelly and the UCB-derived stem cells?

Wharton’s jelly contains primarily mesenchymal stem cells, while the UCB contains other kind of stem cells (haematopoietic stem cells, endothelial progenitor cells), too. Considering the unit quantity, the number of mesenchymal stem cells is much higher in Wharton’s jelly, than in the UCB.

Why is it worth preserving the Wharton’s jelly-derived stem cells, too?

The reason is that, in case of incidental therapeutic use, these stem cells support the adhesion of UCB-derived stem cells effectively. Their impact mechanism is not fully known yet, but due to their antiphlogistic and immunosuppressive effect, there are several examples of using Wharton’s jelly-derived stem cells together with UCB-derived ones. Therapies using exclusively mesenchymal stem cells for treating GVHD (graft versus host disease) and juvenile diabetes (diabetes mellitus type 1 – T1DM) are undergoing clinical trials. Cultures of mesenchymal stem cells are easy to grow and, hence, practically smaller amounts can be used to generate masses of cells that can be effectively used in later therapies as well.

Flags Widget powered by AB-WebLog.com.